SARS-CoV-2 Sequel: Pulmonary Mucormycosis with a Mycotic Aneurysm in a Transplant Recipient

Definition, diagnosis, and management of COVID-19-associated pulmonary mucormycosis: Delphi consensus statement from the Fungal Infection Study Forum and Academy of Pulmonary Sciences, India

“…However, no more than 40 incidents of CAPM have been published globally. 1 , 20 , 21 , 22 , 23 , 24 Thus, there is a possibility of gross under-reporting of the number of patients with CAPM.…”

“…Mycotic aneurysms encountered in CAPM have the potential to cause fatal or severe haemoptysis. 22 , 24 , 30 Hence, a cautious approach is required when carrying out flexible bronchoscopy, bronchoalveolar lavage, or biopsies in patients with massive haemoptysis or mycotic aneurysms. Notably, the bronchoscopy unit should be equipped to handle emergencies, such as severe bleeding following diagnostic bronchoscopies.…”

Pulmonary Artery Pseudoaneurysm in COVID-19-Associated Pulmonary Mucormycosis: Case Series and Systematic Review of the Literature

“…Of these, we could identify one additional case of CAPM with PAP (Table 1 ). [ 7 ] Dantis et al reported the case of a 46-year old renal transplant recipient on immunosuppressive therapy developed CAPM seven weeks following COVID-19 illness. The patient was successfully managed with liposomal amphotericin-B and surgery.…”

“…While COVID-19-associated pulmonary mucormycosis (CAPM) has been described,[ 4 – 6 ] pulmonary artery pseudoaneurysm (PAP) in CAPM is rare. [ 7 ] Herein, we report on five cases of CAPM with PAP. We also systematically review the literature for additional cases and discuss the challenges in the management of CAPM with PAP.…”

Bronchial wall necrosis secondary to mucormycosis following SARS-Cov2 infection: A case report

“…Immunocompromised patients are the leading group who are affected by these microorganisms. In addition, infections caused by Mucorales are gradually being documented in patients with diabetes mellitus, neutropenia, chemotherapy, and steroid use [16] , [17] , [18] , [19] .Yet, the most rampant predisposing factor for mucormycosis in COVID-19 patients is diabetes mellitus [20] , [21] , [22] . The most prevalent clinical manifestations of mucormycosis are rhino-orbital-cerebral, pulmonary, cutaneous, gastrointestinal, and disseminated forms [ 3 , 23 ].…”